Everand Logo

Welcome to Everand!

  • STAT

    Ahead of Geron blowup, warning signs were visible for those willing to see them

    Biotech investing is hard and humbling. But in this case, there were red flags to see if you cared to look.
    by Adam Feuerstein Sep 27, 2018 3 minutes

    I was right about Geron (GERN).

    Janssen, the pharma arm of Johnson & Johnson, decided to end a partnership with Geron to develop the blood disease drug imetelstat. And as you might expect, Janssen’s no-go decision caused Geron shares to plunge. The stock is down 62 percent to $2.39 in Thursday trading.

    I don’t say this to taunt the biotech’s supporters who took a financial hit Thursday. But this

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About Pfizer’s DTC Platform, Sandoz’s Feud With A U.K. Trade Group, And More
    Pfizer filed a trademark application last month for a website and app providing medical information and mail-order pharmacy and telehealth services to U.S. patients.
    STAT1 min read
    STAT+: Microsoft’s Peter Lee Says ChatGPT Shouldn’t Be Used For Initial Diagnosis
    Speaking at #STATBreakthrough Summit, Microsoft’s Peter Lee talked about how ChatGPT and generative AI still have tricky blindspots.
    STAT1 min read
    Opinion: STAT+: How AI Can Help Satisfy FDA’s Drug, Device Diversity Requirements
    To meet the Food and Drug Omnibus Reform Act, companies must rethink their current clinical trial strategies. Including AI and machine learning approaches can help.

    Related Books & Audiobooks